CSL’s new global corporate headquarters in Melbourne has been awarded a five-star rating from the Green Building Council of Australia.
19 Oct 2022
MELBOURNE, AUSTRALIA: Global biotechnology leader CSL’s new global corporate headquarters has been awarded a five-star rating from the Green Building Council of Australia.
In August this year, CSL announced new carbon targets as part of its broader sustainability strategy and a commitment to a healthier world. CSL’s Chief operating Officer Mr. Paul McKenzie said the rating was further recognition of this pursuit.
“We have been clear that we want to deliver our therapeutics and vaccines in a more efficient and environmentally respectful way. We are a growing organisation, and we know that all development must happen in an environmentally responsible manner. The rating afforded to CSL Melbourne is a further example of this,” he said.
The Melbourne facility joins other CSL expansion projects such as the new M600 facility in Marburg and the next-generation influenza vaccine facility in Victoria as having specific sustainability features as a priority in their design. Some of the features of the headquarters include:
- Sourcing of building materials from responsible manufacturers
- Recycling of building materials and diverting of construction waste from landfill
- Electrical vehicle charging stations
- Optimized building insulation and glazing to reduce heating and cooling loads
- Façade designed to reduce the need for artificial lighting
- Highly efficient elevators with regenerative braking
- Water-efficient bathroom facilities and irrigation systems
- Flicker-free lighting and the minimization of glare through windows.
CSL expects to take possession of its new headquarters in the first half of 2023. The facility includes world-class labs, collaborative office spaces and a Biotech Incubator Laboratory in partnership with the University of Melbourne and the Walter and Eliza Hall Institute (WEHI).
The internationally recognized Green Star rating system sets the standard for healthy, resilient, positive buildings and places, and rewards buildings that reduce the impact of climate change, enhance health and quality of life, and contribute to maintaining a sustainable economy.
CSL Limited (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 30,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL.
For more information visit csl.com.
### ENDS ###